{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:33:01Z","timestamp":1786739581693,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the efficacy of combined intravitreal ranibizumab (IVR) and zone I sparing laser ablation in infants with posterior zone I Retinopathy of Prematurity (ROP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a retrospective, interventional case series including premature infants diagnosed with posterior zone I ROP (n = 24) on ROP screening. Charts and RetCam images of preterm infants with posterior zone I ROP treated with immediate IVR and zone I sparing laser ablation at 4 weeks between April 2016 and September 2019 were reviewed. Data were analyzed and tabulated using frequency and descriptive statistics to describe the demography, morphology, and treatment outcomes. Primary outcome measure was structural outcome at 6 months. It was further categorized as favorable and unfavorable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Twenty-four infants (48 eyes) with a mean gestational age of 28.54 \u00b1 1.98 weeks and birth weight of 1180.33 \u00b1 280.65 grams were analyzed. Thirty-six (75%) eyes had persistent tunica vasculosa lentis and twenty-six (54.1%) eyes had iris neovascularization. All eyes had features of aggressive posterior retinopathy of prematurity (APROP) limited to posterior zone I. The mean duration between IVR and zone I sparing laser ablation was 29.62 \u00b1 6.36 (range: 24-34) days. One infant (2 eyes) received a second IVR treatment for recurrence of plus disease and persistent new vessels close to the fovea. Laser augmentation was done in 13 (27.1%) eyes. A favorable structural outcome was seen in 45 (93.7%) eyes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Posterior zone I ROP presents as APROP. Combined IVR and zone I sparing laser ablation appears effective treatment option in these eyes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_2581_20","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T10:22:48Z","timestamp":1627899768000},"page":"2164-2170","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity"],"prefix":"10.4103","volume":"69","author":[{"given":"Swapnil M","family":"Parchand","sequence":"first","affiliation":[{"name":"Consultant, Vitreo-Retina Services, MGM Eye Institute, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepanshu","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Fellow, Vitreo-Retinal Services, MGM Eye Institute, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Gangwe","sequence":"additional","affiliation":[{"name":"Consultant, Vitreo-Retina Services, MGM Eye Institute, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tripti","family":"Saraogi","sequence":"additional","affiliation":[{"name":"Fellow, Vitreo-Retinal Services, MGM Eye Institute, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepshikha","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Consultant, Cornea and Anterior Segment Services, MGM Eye Institute, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"B1-20240828","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The international classification of retinopathy of prematurity revisited","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"B2-20240828","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/IAE.0b013e3181a68f3a","article-title":"Aggressive posterior retinopathy of prematurity in Asian Indian babies:Spectrum of disease and outcome after laser treatment","volume":"29","author":"Sanghi","year":"2009","journal-title":"Retina"},{"key":"B3-20240828","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ajo.2012.07.012","article-title":"Aggressive posterior retinopathy of prematurity:Risk factors for retinal detachment despite confluent laser photocoagulation","volume":"155","author":"Sanghi","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"B4-20240828","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/archopht.1990.01070040047029","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity:Three-month outcome","volume":"108","year":"1990","journal-title":"Arch Ophthalmol"},{"key":"B5-20240828","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity:Results of early treatment for ROP randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"B6-20240828","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jcjo.2018.03.005","article-title":"Posterior zone I retinopathy of prematurity:Spectrum of disease and outcome after laser treatment","volume":"54","author":"Katoch","year":"2019","journal-title":"Can J Ophthalmol"},{"key":"B7-20240828","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/01.iae.0000244285.79004.e6","article-title":"Zone I retinopathy of prematurity:Clinical characteristics and treatment outcomes","volume":"26","author":"Kychenthal","year":"2006","journal-title":"Retina"},{"key":"B8-20240828","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW):An open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"B9-20240828","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"B10-20240828","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.oret.2017.09.021","article-title":"Supplemental laser for eyes treated with bevacizumab monotherapy in severe retinopathy of prematurity","volume":"2","author":"Tandon","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"B11-20240828","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5935\/0004-2749.20150079","article-title":"Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity","volume":"78","author":"Gunay","year":"2015","journal-title":"Arq Bras Oftalmol"},{"key":"B12-20240828","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ophtha.2016.10.032","article-title":"Efficacy of primary intravitreal Ranibizumab for retinopathy of prematurity in china","volume":"124","author":"Feng","year":"2017","journal-title":"Ophthalmology"},{"key":"B13-20240828","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"Wong","year":"2015","journal-title":"Retina"},{"key":"B14-20240828","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","article-title":"Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity","volume":"245","author":"Chung","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B15-20240828","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00417-010-1375-0","article-title":"Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels","volume":"248","author":"Lee","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B16-20240828","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/IAE.0b013e318296e26d","article-title":"Combined intravitreal Bevacizumab injection and Zone I sparing laser photocoagulation in patients with Zone I retinopathy of prematurity","volume":"34","author":"Kim","year":"2014","journal-title":"Retina"},{"key":"B17-20240828","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/bjophthalmol-2011-300321","article-title":"A Hybrid form of retinopathy of prematurity","volume":"96","author":"Sanghi","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"B18-20240828","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1542\/peds.2005-2749","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"117","year":"2006","journal-title":"Pediatrics"},{"key":"B19-20240828","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.earlhumdev.2007.12.004","article-title":"UK retinopathy of prematurity guideline","volume":"84","author":"Wilkinson","year":"2008","journal-title":"Early Hum Dev"},{"key":"B20-20240828","first-page":"1217","article-title":"Vascularization of the human fetal retina:Roles of vasculogenesis and angiogenesis","volume":"41","author":"Hughes","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B21-20240828","doi-asserted-by":"crossref","first-page":"F371","DOI":"10.1136\/fetalneonatal-2011-301121","article-title":"Aggressive posterior retinopathy of prematurity in large preterm babies in South India","volume":"97","author":"Shah","year":"2012","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"B22-20240828","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ajo.2006.02.018","article-title":"Retinopathy of prematurity:Two distinct mechanisms that underlie zone 1 and zone 2 disease","volume":"142","author":"Flynn","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"B23-20240828","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/eye.2015.240","article-title":"Serial evaluation of retinal vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in zone I","volume":"30","author":"Padhi","year":"2016","journal-title":"Eye (Lond)"},{"key":"B24-20240828","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"B25-20240828","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B26-20240828","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000252970","article-title":"Pulmonary vascular endothelial growth factor expression and desaturated phospholipid content in a chicken model of hypoxia-induced fetal growth restriction","volume":"97","author":"Been","year":"2010","journal-title":"Neonatology"},{"key":"B27-20240828","first-page":"F240","article-title":"Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney","volume":"268","author":"Simon","year":"1995","journal-title":"Am J Physiol"},{"key":"B28-20240828","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"B29-20240828","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti\u2013vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity:A Report by the American Academy of Ophthalmology","volume":"124","author":"Vander Veen","year":"2017","journal-title":"Ophthalmology"},{"key":"B30-20240828","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1167\/tvst.9.8.43","article-title":"Ranibuzumab population pharmacokinetics and free VEGF pharmacodynamics in preterm infants with retinopathy of prematurity in the RAINBOW trail","volume":"9","author":"Fidler","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"B31-20240828","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1167\/iovs.12-10260","article-title":"Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration:A population approach","volume":"54","author":"Xu","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B32-20240828","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3109\/02713683.2015.1084643","article-title":"Effects of intravitreal ranibizumab in the treatment of retinopathy of prematurity in Chinese infants","volume":"41","author":"Yi","year":"2016","journal-title":"Curr Eye Res"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2581_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:30:12Z","timestamp":1786735812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2581_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2581_20","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"2020-08-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}